

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 March 2004 (25.03.2004)

PCT

(10) International Publication Number
WO 2004/024183 A1

- (51) International Patent Classification⁷: **A61K 39/39**, 39/385, 39/00, C07K 14/435, A61P 3/04
- (21) International Application Number:
PCT/DK2003/000592
- (22) International Filing Date:
12 September 2003 (12.09.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
PA 2002 01345 12 September 2002 (12.09.2002) DK
60/410,164 12 September 2002 (12.09.2002) US
- (71) Applicant (*for all designated States except US*):
PHARMEXA A/S [DK/DK]; Kogle Allé 6, DK-2970
Hørsholm (DK).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **BØVING, Tine**,
Elisabeth, Gottschalk [DK/DK]; c/o PHARMEXA A/S,
Kogle Allé 6, DK-2970 Hørsholm (DK). **KLYSNER**,
Steen [DK/DK]; c/o PHARMEXA A/S, Kogle Allé 6,
DK-2970 Hørsholm (DK).
- (74) Agent: INSPICOS A/S; Bøge Allé 3, P.O. Box 45,
DK-2970 Hørsholm (DK).
- (81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, EG, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: IMMUNIZATION AGAINST AUTOLOGOUS GHRELIN

(57) Abstract: Disclosed are novel methods that generally rely on immunization against autologous ghrelin. Immunization is preferably effected by administration of analogues of autologous ghrelin, said analogues being capable of inducing antibody production against the autologous ghrelin polypeptides. Especially preferred as an immunogen is autologous ghrelin, which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Also disclosed are nucleic acid vaccination against ghrelin and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.